Gastroparesis Drugs Market Size

Global Gastroparesis Drugs Market size was valued at USD 5.7 billion in 2023 and is poised to grow from USD 6.01 billion in 2024 to USD 9.23 billion by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032). 

The gastroparesis drugs market is experiencing steady growth, primarily driven by the increasing prevalence of diabetes, which is a leading cause of gastroparesis, along with rising awareness about gastrointestinal disorders. The market is benefiting from a growing preference for non-invasive and symptom-targeted therapies. Among the drug classes, proton pump inhibitors and prokinetic agents are widely used due to their effectiveness in managing symptoms like nausea, bloating, and delayed gastric emptying. Diabetic gastroparesis is the most prominent indication segment, reflecting the global rise in diabetes-related complications.

Retail pharmacies continue to be the primary distribution channel for gastroparesis drugs, although online pharmacies are increasingly gaining popularity for their accessibility and convenience. The market remains competitive, with major pharmaceutical players focusing on research and development, strategic partnerships, and expanding their therapeutic portfolios to meet evolving patient needs and regulatory requirements.

Regionally, North America dominates the market, supported by strong healthcare infrastructure, high diagnosis rates, and active research efforts. The United States remains at the forefront due to widespread awareness and availability of advanced treatment options. Europe also holds a significant market share, with countries like Germany and the UK advancing in diagnostics and patient care.

How is Artificial Intelligence Transforming the Gastroparesis Drugs Market?

Artificial Intelligence (AI) is significantly shaping the gastroparesis drugs market by accelerating drug discovery, enhancing diagnostic precision, and streamlining clinical trials. AI-powered platforms are being increasingly adopted by pharmaceutical companies to identify potential drug candidates, predict patient response to treatments, and optimize trial designs ultimately reducing time-to-market and development costs.

In March 2024, pharmaceutical company NeuroGasTx partnered with AI firm Quris-AI to utilize AI-based patient simulation models for accelerating clinical trials of its investigational drug for diabetic gastroparesis. This collaboration aims to enhance trial efficiency by identifying ideal patient cohorts, minimizing adverse reactions, and improving success rates. Such AI integrations are setting new standards in precision medicine for gastrointestinal conditions, particularly gastroparesis.